THE US Food and Drug Administration FDA today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer, and extends to patients who have not received prior chemotherapy.
Bavencio appears to work by helping the body's immune system attack cancer cells by blocking their interaction with specific proteins.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 17
